# FDA 483 - MD Anderson Cord Blood Bank - March 24, 2022

Source: https://www.keypedia.com/records/483/md-anderson-cord-blood-bank/db3527e9-212a-4b43-9ddf-f02d0dafd663

> FDA 483 for MD Anderson Cord Blood Bank on March 24, 2022. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: MD Anderson Cord Blood Bank
- Inspection Date: 2022-03-24
- Product Type: biologics
- Office Name: Division of Human and Animal Food Operations - West III
- Summary: An FDA inspection of MD Anderson Cord Blood Bank in Houston, TX, identified a significant quality system deficiency. The firm lacked written procedures for reprocessing cord blood batches, specifically for a particular machine, despite having reprocessed a unit due to low cell recovery.

## Related Officers

- [Compliance Officer at FDA](https://www.keypedia.com/people/lauren-m-lilly/41582ad0-67b1-4c60-99e2-c1e3c63811c2)
- [Investigator](https://www.keypedia.com/people/darla-j-christopher/64d3f47f-f3c0-4cfd-a3e8-4dc0e69d04bd)

Company: https://www.keypedia.com/companies/md-anderson-cord-blood-bank/a3827992-3da6-4434-846a-88b7095d8dbe

Office: https://www.keypedia.com/offices/division-of-human-and-animal-food-operations-west-iii/2cda09a5-06c4-433f-9df0-0d7903a6efab